Your browser doesn't support javascript.
loading
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway.
Mao, Lili; Dai, Jie; Cao, Yabin; Bai, Xue; Sheng, Xinan; Chi, Zhihong; Cui, Chuanliang; Kong, Yan; Zhang, Yanxiang; Wu, Lin; Wang, Xuan; Tang, Bixia; Lian, Bin; Yan, Xieqiao; Li, Siming; Zhou, Li; Wei, Xiaoting; Li, Caili; Qi, Zhonghui; Si, Lu; Guo, Jun.
Affiliation
  • Mao L; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Dai J; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Cao Y; Kiang Wu Hospital, Macau, China.
  • Bai X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Sheng X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Chi Z; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Cui C; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Kong Y; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhang Y; Berry Oncology Corporation, Beijing, China.
  • Wu L; Berry Oncology Corporation, Beijing, China.
  • Wang X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Tang B; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Lian B; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Yan X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Li S; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhou L; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Wei X; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Li C; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Qi Z; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Si L; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: silu15_silu@126.com.
  • Guo J; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address: guoj307@126.com.
Eur J Cancer ; 148: 297-306, 2021 05.
Article in En | MEDLINE | ID: mdl-33770575
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Skin Neoplasms / Biomarkers, Tumor / Cyclin-Dependent Kinase 4 / Melanoma / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Skin Neoplasms / Biomarkers, Tumor / Cyclin-Dependent Kinase 4 / Melanoma / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2021 Type: Article Affiliation country: China